Funding

siRNA
#Biotechnology #Dermatology #Funding #Immuno-dermatology #siRNA

Is this a novel approach to immuno-dermatology? 

Aldena Therapeutics, a biotech company that is pioneering siRNA-based therapies for dermatological indications, has updated its immuno-dermatology pipeline, appointed a Scientific Advisory Board (SAB), and announced $30 million financing by Medicxi.  Pipeline  Under the leadership of Thibaud Portal, CEO of Aldena, the company’s goal is to develop advanced, long-lasting treatments… Read More

#Business & Investment #News

Bacteria in Petri dishes
#Antibiotics #Antibodies #Antimicrobial resistance (AMR) #Antimicrobials #Cystic fibrosis #Funding #LifeArc

£3m drug discovery programme for cystic fibrosis

UK-based Cystic fibrosis (CF) Syndicate in Antimicrobial Resistance (AMR) has announced a £3 million ($3.6 million) Collaborative Discovery Programme for drug discovery innovators to accelerate the development of new treatments for people with CF. Funded by UK medical research charity LifeArc, the programme will support approximately… Read More

#News

Neuron and antibodies
#AI / data analytics / healthtech / informatics #Antibodies #Antiverse #Drug discovery #Funding #Investment #Machine learning

AI company raises $3m to develop antibodies targeting GPCRs

Antiverse has successfully identified functional antibody clusters targeting two G-protein-coupled receptors (GPCRs), both displaying versatile binding profiles and nanomolar affinity.  The company has raised $3 million in funding, which will enable in-house development of the antibodies showing the highest affinity blocking function. The antibodies were identified using Antiverse’s proprietary… Read More

#News

#Funding #Immunology / Virology & Vaccines #Investment #mRNA #mRNA-based vaccines

Funding injection for Strep A vaccine research

A research effort to develop an mRNA vaccine against Group A Streptococcus (Strep A) has secured almost $8 million in funding.  The Leducq Foundation has announced support for the University of Queensland-led project that could reduce Strep A infections, which cause more than 500,000 deaths a year… Read More

#News

Researcher pipetting samples in microplate
#Drug delivery #Funding #Genetics #Genetics / genomics #Investment #Start-ups

Start-up aims to advance transformative genetic medicines

Aera Therapeutics has launched with a vision to “unlock the potential of genetic medicines across a wide range of modalities and therapeutic areas”.   The company’s delivery platform is based on research conducted in the laboratory of scientific founder Feng Zhang and aims to address the limitations of… Read More

#News #Start-up Zone

#ALS #Cerevance #Financing #Funding #Neurology #Parkinson's #Schizophrenia

$116 million financing will support neurological disease trials

Cerevance has expanded its Series B funding round with an additional close of $51 million, bringing the total to $116 million.  The financing will support upcoming clinical trials focused on Parkinson’s disease, Amyotrophic Lateral Sclerosis (ALS), and schizophrenia.   “We are thrilled to secure additional funding from world-class investors who strongly… Read More

#Business & Investment #News

#DNA #Financing #Funding #Investment #Synthetic biology

$24 million funding to accelerate synthetic biology research

Evonetix has completed a $24 million financing round, extending its total series B funding to over $54 million.   The fundraise was led by existing investor Foresite Capital, with Molten Ventures, Morningside, DCVC, Cambridge Consultants, Civilization Ventures and Providence also participating in the round.  The investment will enable the continued development… Read More

#Business & Investment #News

Professor Stefano Pagliara
#Antibiotic resistance #Antibiotics #Antimicrobial resistance (AMR) #European Research Council #Funding

$2 million awarded to antibiotic resistance researcher

A major boost of £1.76 million ($2.16 million) will fund research designed to stop antibiotics failing, to help mitigate the rising threat of antibiotic resistance.  Professor Stefano Pagliara, at the University of Exeter, has received the award to advance his work on controlling the processes and biological… Read More

#News

microRNA
#AI / data analytics / healthtech / informatics #Artificial intelligence (AI) #Funding #Investment #Machine learning #Molecular Biology #RNA #Start-ups

$35 million to advance AI-driven RNA structure platform

Atomic AI, a biotechnology company fusing machine learning with structural biology to unlock RNA drug discovery, launched today with a $35 million Series A round.  The financing was led by Playground Global, with participation from 8VC, Factory HQ, Greylock, NotBoring, AME Cloud Ventures, and renowned angel investors including GitHub ex-CEO… Read More

#Business & Investment #News #Start-up Zone

#AI / data analytics / healthtech / informatics #Clinical trial design #Funding #Psychedelics #Start-ups

What will the 2023 drug discovery landscape look like?

Listen to this article on the DDW podcast: DDW Multimedia Editor Megan Thomas observes the 2023 drug discovery landscape, speaking to industry experts and looking at the foundations of 2022 on which next year will lean. Virtual clinical trials ‘Virtual’ and ‘technology’ are concepts which are readily exchanged in this industry,… Read More

#Exclusive Content #Trends & Analysis

Cancer research
#Cancer immunotherapy #Cancer research #Funding #Immunotherapy #Investment #ISA Pharmaceuticals #Oncology #Ophthalmology #Synthetic biology

$5 million to fund trial of therapy for uveal melanoma

Cancer Focus Fund is investing $5 million in funding to support ISA103, ISA Pharmaceuticals’ PRAME-targeting immunotherapy, in a first-in-human study for the treatment of uveal melanoma, a rare ocular cancer.  Cancer Focus Fund was established in collaboration with The University of Texas MD Anderson Cancer Center to provide funding and… Read More

#Business & Investment #Cancer Research #News

Neuronal inclusions in Huntington’s disease
#Alchemab #Antibodies #Biologics / Biotechnology #Funding #Medicines Discovery Catapult #Neurodegenerative disorders #Neuroscience

£1.7M awarded to accelerate therapy for Huntington’s disease

Biotechnology company Alchemab Therapeutics has been awarded a grant of £1.7 million (US$2 million) from Innovate UK’s Biomedical Catalyst 2022 funding competition, to accelerate development of a first-in-class disease modifying therapy for Huntington’s disease.   Working in collaboration with Medicines Discovery Catapult (MDC), Alchemab is carrying out preclinical… Read More

#News

Big Ben and Houses of Parliament
#Cancer research #Drug discovery #Funding #Mental health #UK government

Cancer research to get £22.5 million share of UK fund

The UK government has promised that patients will benefit from cutting-edge new treatments with the introduction of a Vaccine Taskforce style approach to tackling health challenges.  The government has committed over £113 ($135) million to fund research into four healthcare missions – cancer, obesity, mental health and addiction. Building… Read More

#Cancer Research #News

#Biologics #Biotechnology #Funding #Seed funding #Therapeutics

How will $41 million be used to fight chronic and age-related diseases? 

Juvena Therapeutics, a biotechnology company scaling a computational platform to map the therapeutic potential of secreted proteins, has raised $41 million in an oversubscribed Series A, bringing its total funding to $50 million. The new funding will power the expansion of Juvena’s drug discovery platform and advance the company’s biologics… Read More

#Business & Investment #News

Rishi Sunak presenting the UK budget
#Academy of Medical Sciences #BioIndustry Association #Biomedical research #Cancer Research UK #Economy #Funding #Investment #UK budget #UK economy #UK government

UK biomedical organisations warn against research cuts 

Ahead of the UK Government’s Autumn Statement on Thursday, leading biomedical research companies, charities and institutions have called for the Chancellor to place medical and health research at the heart of plans for growth.  The letter has been signed by the Academy of Medical Sciences, Pfizer, Wellcome,… Read More

#News

#Biosciences #Funding #Liver disease #Phenotyping

$30 million financing for RNA therapies for chronic liver diseases 

Ochre Bio, a company developing therapies for liver health challenges, has closed $30 million in Series A financing, which will be used to translate the insights from their discovery research into RNA-based drug candidates, and then test these in human livers at their recently launched ‘Liver ICUs’ across the… Read More

#News